-
Part 3 | Session 3 Session 3.2: Live Cases & Discussions
-
Part 3 | Session 4 Session 3.3: Controversies
-
Part 3 | Session 5 Day Three Close
-
Part 1 | Session 1 Day Welcome: Structural Heart Disease
-
Part 1 | Session 3 Session 1.2 Live Cases & Discussions
-
Part 1 | Session 4 Session 1.3: Revalving for Transcatheter Heart Valve Failure
-
Part 1 | Session 5 Session 1.4: Live Cases & Discussions
-
Part 1 | Session 6 Day One Close
-
Part 2 | Session 1 Day Welcome: Complex PCI
-
Part 2 | Session 2 Session 2.1: Coronary Calcifications Updates
-
Part 2 | Session 3 Session 2.2: Live Cases & Discussions
-
Part 2 | Session 4 Session 2.3: Imaging Focus
-
Part 2 | Session 5 Session 2.4: Live Cases & Discussions
-
Part 2 | Session 6 Day Two Close
-
Part 3 | Session 1 Day Welcome: Debates & Controversies
TIO 2024 brought together an outstanding international faculty, creating an unparalleled interactive experience that will keep the global interventional cardiology community up-to-date with the latest advancements in transcatheter treatment strategies. Featuring a combination of expert opinions, engaging discussions, insightful presentations and live cases from prominent medical centres on both sides of the Atlantic, TIO delivered the highest-quality CME-accredited education.
Related Content:
Key Learning Objectives
- Review planning and valve selection strategies in patients with prior valve failure
- Summarise recent repair and replacement data in mitral and tricuspid regurgitation
- Select suitable tools for undertaking PCI in calcified lesions
- Optimise use of imaging in daily practice
- Outline the pros and cons of using P2Y12 inhibitors universally following PCI
- Identify situations where an IVUS or OCT-guided approach are preferable
- Discuss the possible implications of TAVR becoming a care option in asymptomatic aortic stenosis
Target Audience
- Interventional Cardiologists
- Surgeons with an interest in transcatheter treatment strategies for coronary and structural heart disease
- Interventional Cardiology Nurses
More from this programme
Part 1
Day One: Structural Heart Disease
Part 2
Day Two: Complex PCI
Part 3
Day Three: Debates & Controversies
Faculty Biographies
Nicolas M Van Mieghem
Medical Director
Prof Van Mieghem initially intended to train as a cardiac surgeon but decided to specialise in interventional cardiology instead, following advice from a mentor. This decision was cemented when he read the first-in-human case report of transcatheter aortic valve implantation (TAVI) in Circulation by Alain Cribier in 2002. Prof Van Mieghem believes that great cardiologist genuinely cares for their patients. He names Gary Roubin, Dr Manu Malbrain and Professor Patrick Serruys among his mentors.
His current research focuses on cerebral embolic protection during TAVI and the search for improved large bore closure devices. He works actively in expanding TAVI indications, most notably TAVI as a means to further unload the left ventricle in heart failure patients with moderate aortic stenosis (the TAVR UNLOAD trial). Prof Van Mieghem is also involved in the development and dispersion of mechanical circulatory support (MCS) devices as well as transcatheter mitral…
Kendra J Grubb
Surgical Director
Dr Kendra Grubb is the surgical director of the Emory Structural Heart and Valve Center. She is also an associate professor of surgery at Emory University School of Medicine.
Kendra is a champion for women's heart disease and is dedicated to improving the lives of all patients through innovation, collaboration and a patient-centred approach to the treatment of cardiovascular disease.
Her clinical interests include valve repair or replacement, coronary artery bypass graft surgery (CABG), transcatheter aortic valve replacement (TAVR) and hybrid coronary revascularization.
Dr Grubb research interests are innovative cardiac surgery technologies. She has led and participated in multiple clinical trials of innovative cardiac surgery technologies, including studies of transcatheter aortic valve replacement (TAVR), MitraClip percutaneous therapy and the GORE® conformable TAG® thoracic endoprosthesis for the primary treatment of…
Giuseppe Tarantini
Prof Giuseppe Tarantini is the Head of the Interventional Cardiology Unit within the Department of Cardiac, Thoracic, and Vascular Sciences at the University of Padua Medical School, Padua, IT. He is a globally recognised researcher specialising in ischemic heart disease, structural heart disease, and cardiomyopathies.
Prof Tarantini serves as the primary operator for a diverse array of interventional procedures, encompassing coronary interventions (including atherectomies), peripheral interventions (such as carotid and renal procedures), and structural heart interventions (involving ASDs, PFOs, TAVI, and AVP).
In addition to his clinical work, Prof Tarantini is a distinguished faculty member at various international conferences, including Transcatheter Cardiovascular Therapeutics (TCT), the Congresso della Societa Italiana di Cardiologia Invasiva (SICI-GISE), Euro PCR, and the European Society of Cardiology (ESC). He boasts a publication record of 245 clinical…
Comments